ArticleCanada communicable disease report = Releve des maladies transmissibles au Canada2019
Addressing the rising rates of gonorrhea and drug-resistant gonorrhea: There is no time like the present.
Article in Canada communicable disease report = Releve des maladies transmissibles au Canada, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- A systematic review of Neisseria gonorrhoeae drug resistance development in South Africa.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Pooled it
- An antibody-drug conjugate active against antibiotic-resistantProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Local Prevalence of Ceftriaxone Resistance Informs Optimal Deployment of New Gonorrhea Treatments.Open forum infectious diseases · 2026Article
- Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors withJournal of medicinal chemistry · 2026Article
- Article
- Effectiveness of the four-component protein-based meningococcal vaccine againstCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Article
- Efficacy and Safety of Gepotidacin as Treatment of Uncomplicated Urogenital Gonorrhea (EAGLE-1): Design of a Randomized, Comparator-Controlled, Phase 3 Study.Infectious diseases and therapy · 2023Article
- Identification of Emerging Multidrug-ResistantMedical sciences (Basel, Switzerland) · 2023Article
- Neisseria gonorrhoeae co-opts C4b-binding protein to enhance complement-independent survival from neutrophils.PLoS pathogens · 2023Article
- Factors associated with intention to receive vaccines for bacterial sexually transmitted infections among young HPV-vaccinated Canadian women.Canadian journal of public health = Revue canadienne de sante publique · 2022Article
- Evaluation of the Hologic Aptima Combo 2 Assay for Detection of Neisseria gonorrhoeae from Joint Fluid Specimens.Journal of clinical microbiology · 2022Article
- Bioinformatics tools used for whole-genome sequencing analysis of Neisseria gonorrhoeae: a literature review.Briefings in functional genomics · 2022Review
- Antibacterial Effects of Flavonoids and Their Structure-Activity Relationship Study: A Comparative Interpretation.Molecules (Basel, Switzerland) · 2022Review
- Unusual presentation of a periurethral abscess following infection withBMJ case reports · 2022Article
- Potential interactions between the pathways to diagnosis of HIV and other STIs and HIV self-testing: insights from a qualitative study of gay, bisexual and other men who have sex with men in Singapore.Sexually transmitted infections · 2021Article
- Are Swedish swingers a risk group for sexually transmitted infections?International journal of STD & AIDS · 2021Article
- Article
- The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Commentary: Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter.Frontiers in public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing rates of gonococcal (GC) infection and antimicrobial resistant (AMR) GC, are a serious public health concern for Canada and around the world. Previously recommended treatments are ineffective against many of the gonorrhea strains circulating today. The current recommendation for combination therapy is now being threatened by globally emerging and increasingly resistant strains. It is important that coordinated efforts be made now to ensure these new global strains do not become established in Canada. Otherwise, we will be faced with the possibility of persistent GC infection which can lead to pelvic inflammatory disease, infertility and chronic pelvic pain in women; and epididymitis in men. The presence of GC can also increase the risk of HIV acquisition and transmission. There are a number of reasons why we are facing this public health threat. GC infection is often asymptomatic and it is highly transmissible. People may hesitate to seek testing (or to offer testing). Treatment is complex: recommendations vary by site of infection and risk of resistance. Sexual contact during travel is an important source of imported emerging resistant global strains. The new screening and diagnostic Nucleic Acid Amplification Test (NAAT) is excellent but has decreased the number of cultures being done and therefore our capacity to track AMR-GC. There are four key actions that clinicians and front-line public health professionals can take to stem the increase in rates of GC and drug resistant GC. First, normalize and increase GC screening based on risk factors and emphasize the need for safer sex practices. NAAT is useful for screening, but culture is still needed for extra-genital sites. Second, conduct pretravel counselling and include a travel history as part of the risk assessment. Third, use culture along with NAAT to establish the diagnosis and follow up for test-of-cure. Finally, refer to the most current
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.